BCAR1/p130Cas expression in untreated and acquired tamoxifen‐resistant human breast carcinomas

High BCAR1/p130Cas expression in primary breast tumour cytosol predicts a poor chance of response recurrent disease to tamoxifen treatment in patients with oestrogen receptor (ER)–positive breast carcinomas. In this study, we assessed whether BCAR1/p130Cas expression is altered during acquisition of anti‐oestrogen resistance. BCAR1/p130Cas protein was quantitatively measured by chemiluminescent Western blot analysis in the cytosol of 34 predominantly ER+ carcinomas that initially responded to primary tamoxifen treatment and subsequently progressed (n = 22 ) or developed during adjuvant tamoxifen treatment (n = 12) and compared to 54 untreated ER+ human breast carcinomas. We did not detect significant differences in the level of BCAR1/p130Cas protein in untreated and acquired tamoxifen‐resistant carcinomas. Our results indicate that in tumour progression towards tamoxifen resistance, increase of BCAR1/p130Cas may be only one of the molecular mechanisms. Thus, high BCAR1/p130Cas protein levels appear to be a hallmark for intrinsic resistance to tamoxifen in breast carcinomas. Int. J. Cancer 89:465–468, 2000. © 2000 Wiley‐Liss, Inc.

[1]  G. O'Neill,et al.  Integrin signalling: a new Cas(t) of characters enters the stage. , 2000, Trends in cell biology.

[2]  S. van der Flier,et al.  BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells. , 2000, Journal of the National Cancer Institute.

[3]  J. Foekens,et al.  Bcar1/p130Cas Protein and Primary Breast Cancer: Prognosis and Response to Tamoxifen Treatment. , 2000, Journal of the National Cancer Institute.

[4]  J. Foekens,et al.  Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. , 2000, Journal of the National Cancer Institute.

[5]  S. Hayashi,et al.  Translocation of ornithine decarboxylase to the surface membrane during cell activation and transformation , 1999, The EMBO journal.

[6]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[7]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[8]  G. Rodan,et al.  Tyrosine Phosphorylation of p130Cas Is Involved in Actin Organization in Osteoclasts* , 1998, The Journal of Biological Chemistry.

[9]  K. Vuori,et al.  CAS/Crk Coupling Serves as a “Molecular Switch” for Induction of Cell Migration , 1998, The Journal of cell biology.

[10]  S. Hanks,et al.  Identification of p130Cas as a Mediator of Focal Adhesion Kinase–promoted Cell Migration , 1998, The Journal of cell biology.

[11]  A. Bouton,et al.  Detection of distinct pools of the adapter protein p130CAS using a panel of monoclonal antibodies. , 1997, Hybridoma.

[12]  C. Osborne,et al.  Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors. , 1997, Cancer research.

[13]  M. Dowsett,et al.  A novel estrogen receptor variant mRNA lacking exons 4 to 6 in breast carcinoma , 1997, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  M. Dowsett,et al.  Oestrogen receptor mutants and variants in breast cancer. , 1997, European journal of cancer.

[15]  S. Shousha,et al.  human breast cancer: functional analysis and clinical , 2022 .

[16]  J Isola,et al.  Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Ruoslahti,et al.  Introduction of p130cas signaling complex formation upon integrin-mediated cell adhesion: a role for Src family kinases , 1996, Molecular and cellular biology.

[18]  M. Dowsett,et al.  Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. , 1995, Cancer research.

[19]  Y. Yazaki,et al.  Integrin-mediated Cell Adhesion Promotes Tyrosine Phosphorylation of p130, a Src Homology 3-containing Molecule Having Multiple Src Homology 2-binding Motifs (*) , 1995, The Journal of Biological Chemistry.

[20]  S. Bockholt,et al.  Adhesion-induced tyrosine phosphorylation of the p130 src substrate. , 1995, Journal of cell science.

[21]  M. Dowsett,et al.  Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. , 1995, Cancer research.

[22]  S. Ogawa,et al.  A novel signaling molecule, p130, forms stable complexes in vivo with v‐Crk and v‐Src in a tyrosine phosphorylation‐dependent manner. , 1994, The EMBO journal.

[23]  T. Agthoven,et al.  Induction of antiestrogen resistance in human breast cancer cells by random insertional mutagenesis using defective retroviruses: identification of bcar-1, a common integration site. , 1993, Molecular endocrinology.

[24]  R. Sutherland,et al.  Oestrogen receptor gene structure and function in breast cancer , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[26]  Early Breast Cancer Trialists' Collaborative Group.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[27]  Earlybreastcancertrialistscol,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[28]  W. McGuire,et al.  Variant human breast tumor estrogen receptor with constitutive transcriptional activity. , 1991, Cancer research.

[29]  V. Jordan,et al.  Endocrine pharmacology of antiestrogens as antitumor agents. , 1990, Endocrine reviews.